High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab

Published:2017-05-02 Issue:1 Volume:28 Page:119-125
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Hattori Yosuke¹,Kojima Toshihisa²,Kaneko Atsushi¹,Kida Daihei¹,Hirano Yuji³,Fujibayashi Takayoshi⁴,Yabe Yuichiro⁵,Oguchi Takeshi⁶,Kanayama Yasuhide⁷,Miyake Hiroyuki⁸,Kato Takefumi⁹,Takagi Hideki¹⁰,Hayashi Masatoshi¹¹,Ito Takayasu¹²,Shioura Tomone¹³,Takahashi Nobunori²,Ishikawa Hisato¹⁴,Funahashi Koji¹⁵,Ishiguro Naoki²

Affiliation:

1. Department of Orthopaedic Surgery and Rheumatology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan;

2. Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan;

3. Department of Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan;

4. Department of Orthopaedic Surgery, Konan Kosei Hospital, Konan, Japan;

5. Department of Rheumatology, Japan Community Healthcare Organization Tokyo Shinjuku Medical Center, Tokyo, Japan;

6. Department of Orthopaedic Surgery, Anjo Kosei Hospital, Anjo, Japan;

7. Department of Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan;

8. Department of Orthopaedic Surgery, Ichinomiya Municipal Hospital, Ichinomiya, Japan;

9. Kato Clinic, Okazaki, Japan;

10. Department of Orthopaedic Surgery, Nagoya Central Hospital, Nagoya, Japan;

11. Department of Rheumatology, Nagano Red Cross Hospital, Nagano, Japan;

12. Ito Seikeigeka, Nagoya, Japan;

13. Shizuoka Kosei Hospital, Shizuoka, Japan;

14. Department of Orthopaedic Surgery, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan;

15. Department of Orthopaedic Surgery, Kariya Toyota General Hospital, Kariya, Japan

Funder

Chugai Pharmaceutical

Pfizer

Abbvie

UCB

Bristol-Myers Squibb

Janssen Pharmaceuticals

Mitsubishi Tanabe Pharma

Takeda Pharmaceutical Compan

Eisai

AbbVie

Astellas Pharma

Taisho Toyama Pharmaceutical Company

Daiichi Sankyo Company

Takeda Pharmaceutical

AYUMI Pharmaceutical

Mitsubishi Tanabe Pharmaceutical

Mitsubishi Tanabe Pharma Corporation

Janssen Pharmaceutical

Daiichi Sankyo

Hisamitsu Pharmaceutical

Otsuka Pharmaceutical

Kaken Pharmaceutical

Abbott Japan

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14397595.2017.1317320

Reference25 articles.

1. Rheumatoid arthritis

2. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis

3. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis

4. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extensive study of CCN4, VCAM-1, MMP-3, and GM-CSF as reliable markers for disease activity in rheumatoid arthritis;Journal of Taibah University Medical Sciences;2024-08

2. Effects of Etanercept and Adalimumab on Serum Levels of Cartilage Remodeling Markers in Women with Rheumatoid Arthritis;Journal of Clinical Medicine;2023-08-09

3. Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis;Heliyon;2023-03

4. Evaluation of Serum Matrix Metalloproteinase-3 as an Objective Indicator for the Disease Activity in Rheumatoid Arthritis Patients Treated With Methotrexate Versus Tocilizumab: 24-week Results From a Prospective Randomized Controlled Study;J RHEUMAT DIS;2022

5. Evaluation of Serum Matrix Metalloproteinase-3 as an Objective Indicator for the Disease Activity in Rheumatoid Arthritis Patients Treated With Methotrexate Versus Tocilizumab: 24-week Results From a Prospective Randomized Controlled Study;Journal of Rheumatic Diseases;2022-04-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3